vs
Side-by-side financial comparison of CoastalSouth Bancshares, Inc. (COSO) and ENANTA PHARMACEUTICALS INC (ENTA). Click either name above to swap in a different company.
CoastalSouth Bancshares, Inc. is the larger business by last-quarter revenue ($21.3M vs $18.6M, roughly 1.1× ENANTA PHARMACEUTICALS INC). CoastalSouth Bancshares, Inc. runs the higher net margin — 31.7% vs -64.1%, a 95.8% gap on every dollar of revenue. CoastalSouth Bancshares, Inc. produced more free cash flow last quarter ($-5.9M vs $-11.8M).
CoastalSouth Bancshares, Inc. is a U.S.-based regional bank holding company. It provides a full range of personal and commercial banking services including deposit accounts, consumer loans, mortgages, commercial financing and wealth management solutions for retail customers and small-to-medium enterprises across the U.S. Gulf Coast region.
Enanta Pharmaceuticals Inc is a clinical-stage biotechnology company that develops innovative antiviral therapies for infectious diseases including hepatitis B virus, respiratory syncytial virus (RSV), and SARS-CoV-2. It operates primarily in the U.S. and global markets, partnering with pharmaceutical firms to advance its small molecule drug candidate pipeline for patients with unmet medical needs.
COSO vs ENTA — Head-to-Head
Income Statement — Q3 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $21.3M | $18.6M |
| Net Profit | $6.7M | $-11.9M |
| Gross Margin | — | — |
| Operating Margin | 41.2% | -60.5% |
| Net Margin | 31.7% | -64.1% |
| Revenue YoY | — | 9.8% |
| Net Profit YoY | — | 46.4% |
| EPS (diluted) | $0.54 | $-0.42 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $18.6M | ||
| Q3 25 | $21.3M | $15.1M | ||
| Q2 25 | $19.9M | $18.3M | ||
| Q1 25 | — | $14.9M | ||
| Q4 24 | — | $17.0M | ||
| Q3 24 | — | $14.6M | ||
| Q2 24 | — | $18.0M | ||
| Q1 24 | — | $17.1M |
| Q4 25 | — | $-11.9M | ||
| Q3 25 | $6.7M | $-18.7M | ||
| Q2 25 | $6.0M | $-18.3M | ||
| Q1 25 | — | $-22.6M | ||
| Q4 24 | — | $-22.3M | ||
| Q3 24 | — | $-28.8M | ||
| Q2 24 | — | $-22.7M | ||
| Q1 24 | — | $-31.2M |
| Q4 25 | — | -60.5% | ||
| Q3 25 | 41.2% | -121.6% | ||
| Q2 25 | 35.4% | -103.2% | ||
| Q1 25 | — | -164.3% | ||
| Q4 24 | — | -138.8% | ||
| Q3 24 | — | -204.4% | ||
| Q2 24 | — | -134.6% | ||
| Q1 24 | — | -192.1% |
| Q4 25 | — | -64.1% | ||
| Q3 25 | 31.7% | -123.6% | ||
| Q2 25 | 30.0% | -99.7% | ||
| Q1 25 | — | -151.7% | ||
| Q4 24 | — | -131.4% | ||
| Q3 24 | — | -197.3% | ||
| Q2 24 | — | -126.1% | ||
| Q1 24 | — | -182.7% |
| Q4 25 | — | $-0.42 | ||
| Q3 25 | $0.54 | $-0.88 | ||
| Q2 25 | $0.57 | $-0.85 | ||
| Q1 25 | — | $-1.06 | ||
| Q4 24 | — | $-1.05 | ||
| Q3 24 | — | $-1.36 | ||
| Q2 24 | — | $-1.07 | ||
| Q1 24 | — | $-1.47 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $37.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $250.4M | $126.6M |
| Total Assets | $2.3B | $329.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $37.4M | ||
| Q3 25 | — | $32.3M | ||
| Q2 25 | — | $44.8M | ||
| Q1 25 | — | $60.2M | ||
| Q4 24 | — | $84.3M | ||
| Q3 24 | — | $37.2M | ||
| Q2 24 | — | $35.8M | ||
| Q1 24 | — | $63.5M |
| Q4 25 | — | $126.6M | ||
| Q3 25 | $250.4M | $64.7M | ||
| Q2 25 | $209.4M | $79.3M | ||
| Q1 25 | — | $93.5M | ||
| Q4 24 | — | $111.8M | ||
| Q3 24 | — | $128.8M | ||
| Q2 24 | — | $148.9M | ||
| Q1 24 | — | $166.1M |
| Q4 25 | — | $329.5M | ||
| Q3 25 | $2.3B | $280.7M | ||
| Q2 25 | $2.2B | $301.0M | ||
| Q1 25 | — | $323.0M | ||
| Q4 24 | — | $348.6M | ||
| Q3 24 | — | $376.7M | ||
| Q2 24 | — | $398.8M | ||
| Q1 24 | — | $413.6M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-5.5M | $-11.7M |
| Free Cash FlowOCF − Capex | $-5.9M | $-11.8M |
| FCF MarginFCF / Revenue | -27.7% | -63.6% |
| Capex IntensityCapex / Revenue | 1.9% | 0.8% |
| Cash ConversionOCF / Net Profit | -0.82× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-18.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-11.7M | ||
| Q3 25 | $-5.5M | $-6.5M | ||
| Q2 25 | $-16.8M | $17.5M | ||
| Q1 25 | — | $-13.5M | ||
| Q4 24 | — | $-16.8M | ||
| Q3 24 | — | $-10.4M | ||
| Q2 24 | — | $-14.8M | ||
| Q1 24 | — | $-28.6M |
| Q4 25 | — | $-11.8M | ||
| Q3 25 | $-5.9M | $-7.9M | ||
| Q2 25 | $-17.9M | $17.4M | ||
| Q1 25 | — | $-16.0M | ||
| Q4 24 | — | $-25.5M | ||
| Q3 24 | — | $-19.4M | ||
| Q2 24 | — | $-21.3M | ||
| Q1 24 | — | $-30.3M |
| Q4 25 | — | -63.6% | ||
| Q3 25 | -27.7% | -52.5% | ||
| Q2 25 | -90.3% | 94.7% | ||
| Q1 25 | — | -107.4% | ||
| Q4 24 | — | -150.6% | ||
| Q3 24 | — | -132.5% | ||
| Q2 24 | — | -118.6% | ||
| Q1 24 | — | -177.5% |
| Q4 25 | — | 0.8% | ||
| Q3 25 | 1.9% | 9.6% | ||
| Q2 25 | 5.5% | 0.8% | ||
| Q1 25 | — | 17.0% | ||
| Q4 24 | — | 51.6% | ||
| Q3 24 | — | 61.3% | ||
| Q2 24 | — | 36.4% | ||
| Q1 24 | — | 9.8% |
| Q4 25 | — | — | ||
| Q3 25 | -0.82× | — | ||
| Q2 25 | -2.82× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
